Member Info for Sisyphus

There's a fine line between dismissing a share at this level and FOMO as appraisal and adoption snowballs. It really screams the perfect juncture for a player like J&J to take this on and scale it exponentially. The proof of effectiveness is out there and rapidly gaining surgeon comment.

Carol Cross CEO has take this from concept, thorough R&D and proving, trialled and accepted by surgeons and now on the cusp of large commercial rollout. At 62yrs of age and with her background and stature I am sure that she sees the best exit strategy is to sell to a big player who can scale up. The huge degree of success in reducing the need for antibiotics in post operative hospital care is evident and becoming globally 'viral' as surgeons and care teams communicate the savings. Steriwave is simple, quick, non-invasive and safe as it does not compromise the nasal biome weeks after the operation. A 75% reduction in the use of antibiotics to treat post op hospital acquired infections seems to be universal when Steriwave is used. That saves hospitals millions of pounds and thousands of days post op intervention and bed-blocking. It's a total no-brainer and just needs a major [probably US] Healthcare company to make her an offer and immediately scale it globally. As she holds 50% or so of the shares it would be a done deal. I mentioned 20p but I personally see it worth a lot more. Hopefully Carol Cross thinks likewise. I really cannot see any other direction than north from here.

Solid results - improving outlook - uplift in divi.

Given the raft of positive news now coming out from surgeons in all quarters of the profession, oropharyngeal, orthopaedics etc I have written to the company to request that they give possible financial projections of uptake. The recent NHS news must have huge potential and it would be great to see some meat on the bones.

Carolyn Cross is 62, has steered Steriwave from concept, through R&D to commercialisation. It's now on the cusp of exponential adoption looking at success rates. Now is the time to put her exit strategy in play as she holds just under 50% of the shares in Ondine. Time to put it into play and watch the multiples scale it. The fact that a phase 3 trial in the USA is happening probably dictates where that bid will come from given the massive stateside potential. Just a matter of time and patience whilst this frustratingly low shareprice plays out.

Company now needs a major player to scale this breakthrough tech. The likes of Halma,Stryker,S&N could all quickly scale Steriwave now its gaining universal recognition and increased adoption. Consultants lead change and Steriwave is changing HAI post surgery. No brainer.

Positive news - escalation of uptake - price falls. Bizarre.

"Surgical site infections are devastating. If you look at a surgical site infection in a total joint replacement, it’s a months-long recovery process,” says Dr. Andrew Glennie, a QEII orthopaedic surgeon and clinical champion for the Steriwave “test-and-try" in Canada.

Steriwave is currently trialing in NHS.

I'm trying in vain to find the terms of the capital expenditure loan. I know it's not for general working expenditure, just for Capex but what are loan terms?

From X.....

Ondine Biomedical

@OndineBio

·

Mar 18

"It is a no-brainer for us and the nurses are very excited to be involved.”

Read about how the team at the #QEII Health Sciences Centre is using Ondine’s Steriwave technology. Special thanks to the

@QEIIFoundation

for funding this year-long study.

I don't think that the true relevance of this contract has been evaluated by the investment community....yet.

NHS policy is used as a guide globally since it's decisions have major effects of its overall budget. This adoption of Steriwave after evaluation of a 6 month pilot was after a stringent cost/benefit analysis by one of its senior assessment authorities. The big point is that it's being used in orthopaedic pre-op which is a field change from the recent 77% reduction in HAI's in London oropharyngeal surgery.

This is a pivotal RNS and exactly what I suspected in my last post. This really does open the door for Steriwave adoption across the NHS. YHEC is one of the prime influences within the NHS and acts as a first mover in many cases of national rollout. Excellent news that their pilot and subsequent appraisal has led to adoption. The cost savings if universally adopted across the NHS would be 'substantial' according to Ondine.

As far as I can make out YHEC is undertaking an economic analysis based on results from primarily the Pontefract trial. I would expect conclusions from that are due any time. Since YHEC is an influencer for NHS policy it will look at savings that adoption of Steriwave could achieve. This could be quite a pivotal time for Ondine. Positive studies across the globe are accumulating.

How on earth is this still independent with all the info finally gaining traction in hospitals and word of mouth initiating the long awaited snowball effect?

This'll get bought out as its tech is gaining greater momentum.

This is a game changer.

The buying of big chunks continues. £175k is a lot of confidence. There is also the compelling case to bring this under the umbrella of eg Halma Stryker or S&N to grab the traction now. Interesting and huge potential. The benefits wrt Mupirocin are constantly being uprated.

Agree. It's like the lull before the big Nike deal was announced a few years ago. The global packaging partner is named and the scale of ReZorce seen, the company and CEO will continue on its trajectory. Steady hands, safe ship, well positioned.

Some stonkingly big buys arriving this afternoon.

That is one of its fundamental selling points and why it has the backing of the global packaging supplier.